Clinical Trial Update: ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 study of CPI-1205 in metastatic castration-resistant prostate cancer have been posted; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• CPI-1205

Snippet

Sponsor: Constellation Pharmaceuticals | Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-10-29